Navigation Links
Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
Date:3/22/2010

dostar Phase IV clinical study verified that Endostar Phase III and IV are comparable and by combining Endostar with standard chemotherapy regimens, this could improve the median survival time and overall survival rate of patients with advanced NSCLC with no significant increase of the adverse effects of chemotherapy.

At the conference, some investigators (such as medical centers in Sichuan and Zhejiang) reported that Endostar was found also significantly effective for the treatment of pleural/ascetic fluid and Gliomas (a type of brain tumor). Currently, there are many on-going clinical studies of Endostar including lung cancer and non-lung cancer (e.g.: Osteosarcoma and Colorectal cancer). Most of them have registered in the http://clinicaltrials.gov , the registry of US National Institutes of Health.

With the successful completion of Endostar's Phase IV clinical study, as required by the new national drug registration law, Endostar is expected to be the first new drug to successfully pass re-registration.

Professor Sun Yan'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
2. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
3. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
6. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
7. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
8. Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News
9. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
10. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
11. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Una presentazione speciale durante la settimana della prevenzione ... di MERG valutare i successi ottenuti grazie all,adozione ... popolazioni di pazienti affetti dalla patologia. ... Fass , MD della Case Western Reserve University, ha ... alla terapia Stretta. Un panel di esperti ha quindi ...
(Date:5/27/2015)... -- Biosensors International Group, Ltd. ("Biosensors " or the ... developer, manufacturer and marketer of innovative medical devices, today ... FY15") and fiscal full year ended 31 March 2015 ... , Q4 FY15: , Total revenue of ... Fiscal Year 2014 ("Q4 FY14") due to licensing revenue ...
(Date:5/27/2015)... , May 27, 2015  PDL BioPharma, Inc. ... John P. McLaughlin , the company,s president and chief ... Healthcare Conference next week in New York City.  The ... June 3, 2015 at 11:30 a.m. EDT. ... the presentation, go to the Company,s website at ...
Breaking Medicine Technology:Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 2Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 3Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 4Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... TRIANGLE PARK, N.C., Jan. 6, 2011 CeNeRx BioPharma, Inc., today ... new formulation of TriRima ™, the company,s novel antidepressant in ... it will be presenting at Biotech Showcase™ ... 11:00 AM PST. TriRima is a member ...
... Pharmasset, Inc. (Nasdaq: VRUS ), announced today positive ... HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase ... dual nucleotide study.   Pipeline Update and ... PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a ...
Cached Medicine Technology:CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 2CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 3Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 ... the first healthcare provider along the Gulf Coast ... management (CCM). In partnership with MD Revolution, a ... a new program that enables healthcare providers to ... reimbursements. This new, user-friendly program is designed to ...
(Date:5/27/2015)... May 27, 2015 CompanionDx ... and somatic genomic analysis in personalized cancer therapy: Non-small ... the American Society of Clinical Oncology (ASCO) as part ... in Chicago. , The molecular and clinical data used ... Atlas (TCGA) database. The study reports improved patient outcomes ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 On June ... advertising agency, will partner with LifeSource to host Donate ... will take place in a LifeSource donor coach outside ... to 4:00 p.m. , Demand for whole blood units ... Illinois, during the summer months. LifeSource requires approximately 1,000 ...
(Date:5/27/2015)... Dallas, Texas (PRWEB) May 27, 2015 ... on the current state of the Omega-3 industry. ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ... Products, Gc Rieber Oils, Camanchaca Fishing Company, Seadragon ...
(Date:5/27/2015)... 2015 SonarMD, LLC, recently ... a first-of-its kind, cloud-based algorithmic process for ... chronic gastrointestinal disease. , Developed by noted ... allows physicians to monitor their patients’ health ... of electronic health assessment surveys. Using nationally ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... West Indies cricket captain Brian Lara has thrown a punch ... opening of a cancer center named after him. ... and management of the Brian Lara Cancer Center for their ... "missed" the (West Indies) the Cricket Board. ,His ...
... people with celiac disease are waiting an average of 13 ... gut disorder caused by gluten intolerance, and can lead to ... is a protein group found in wheat and other flours ... the carbon dioxide (CO2) produced by the yeast and expands ...
... all the wrong reasons. ,Civic authorities ... who use the Hudson River of the potential health problems ... the river after a main broke Friday afternoon. ... in contact with the sewage and ingesting bacteria that could ...
... the seizure drug valporate, which is marketed by Abbott ... their risk of having an infant with mental ... annual meeting of the American Academy of Neurology in ... Meador, professor of neurology at the University of Florida, ...
... underwent a simultaneous liver and kidney transplant at a ... claimed as the first such in the world. ... as primary Hyperoxaluria, in which the liver lacks an ... bones, heart and pancreas. Patients suffering from the disease ...
... who are on estrogen therapy before the age of 65. ... risk of Alzheimers disease or dementia. ,The study showed ... the age of 65 cut their risk of dementia by 50%, ... the age of 65. ,This study was part ...
Cached Medicine News:Health News:Gluten Intolerance Cases Diagnosed Late in UK 2Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:NRI Boy Underwent a Rare Dual Transplant Surgery 2
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Elisa Plate Reader...
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Medicine Products: